A study by The Inc. of the Natural Publishing Group and the authoritative journal Cell Research of the Chinese Academy of Sciences (Cell Research, IF-17.848) published online a study from a team of Shanxi Medical University, Beijing Concord Medical College of the Chinese Academy of Medical Sciences, Peking University, Shenzhen Peking University Hong Kong University of Science and Technology Medical Center, Baidu Corporation, etc., “Whole-genomeing of 508 patients Molecular features with poor prognosis in oedeal squamous cell carcinoma”.
The study presented the largest map of esophageal squamous cell carcinoma (ESCC) genome analysis, sequenced the whole genome of 508 patients with esophageal squamous cancer, and found key molecular characteristics associated with poor prognosis, which was considered to be very useful for the development of ESCC-specific diagnostic and therapeutic biomarkers.
Notably, the paper has three correspondents, including Yanhong Li, Baidu’s founder, chairman and chief executive. Mr Li is not one of the most important authors, but one of the most important. The other two correspondents are The Standing Committee of the Party Committee of Peking University, the Executive Vice President, the Director of the Medical Department, the Director of the Medical Center of the Hong Kong University of Science and Technology of Peking University in Shenzhen, the Chinese Academy of Engineering, And the Deputy Director of the National Key Laboratory of Molecular Oncology of the Chinese Academy of Medical Sciences, Liu Zhihua.
The abstract shows that esophageal squamous cell carcinoma (ESCC) is a type of cancer with poor prognosis, and its molecular cause is not clear. Using 508 ESCC genomes, the team identified five new significant mutation genes and identified mutation profiles associated with metastasis and patient prognosis.
Several functional trials have shown that NFE2L2 in the five genes may play a role in anti-cancer in ESCC, and mutations in NFE2L2 may impair its anti-cancer function and may even have carcinogenic effects. In addition, the team found that NFE2L2 mutations were significantly associated with adverse prognosis of ESCC.
The team also found potential non-coding gene mutations, including hot mutations in the SLC35E2 gene promoter region, which are associated with poor survival rates in patients.
The study found that about 5.9 percent and 15.2 percent of patients had higher tumor mutation burdens or actionable mutations, which could benefit from immunotherapy or targeted therapy.
Overall, the study found coded and uncoded genomic changes associated with esophageal squamous cell carcinoma, and revealed three major subtypes that strongly predicted the prognosis of patients.
The research was funded by the National Key Research and Development Program, the CAMS Medical Innovation Fund, the National Natural Science Foundation of China, the “Three Projects in Health care” in Shenzhen, and the Guangdong Provincial Foundation for Basic and Applied Basic Research. The paper states that none of the authors in the study had a conflict of interest.
In addition, in the final author’s contribution to the paper specifically mentioned that Liu Zhihua, Li Yanhong, Zhan Qimin responsible for the overall guidance of research, design experiments, editing the paper. It is worth noting that the paper begins with a special thankyou to Baidu’s strong support for the project (A special to Mr. Yanhong Li (Baidu) for his generous support of this project).